Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 28 April 2021, 11:33 HKT/SGT
Share:
    

Source: Eisai
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan
Building Dementia Ecosystem

TOKYO, Apr 28, 2021 - (JCN Newswire) - Saitama Resona Bank, Limited, a corporation of the Resona Group, and Eisai Co., Ltd. announced today that both parties have entered into a business alliance agreement for building an ecosystem with the aim of supporting people living with and preventing dementia ("dementia ecosystem"), in order to realize a regional community where citizens of Saitama Prefecture can live with peace of mind for a long time while maintaining their health.

Image of a sustainable community with dementia ecosystem

In Saitama Prefecture, the speed of aging of society is estimated to be at the top level in Japan. Therefore, one of the major issues is making efforts to create a community where people can live with dementia, and prevent the onset of dementia. Through this business alliance, Resona and Eisai will build a "dementia ecosystem" that combines Resona's customer network in Saitama Prefecture and Eisai's wealth of experience and knowledge in drug creation activities and disease awareness activities in the field of dementia, aiming to support Saitama citizens and people working in companies in Saitama prefecture to maintain a healthy life and create a sustainable community.

As the first step in this effort, the customers of the investment trust "SAITAMA RESONA GLOBAL BALANCE PLUS ESG - SaitamaDGs -"(1) handled by Resona will be provided with Eisai's digital tool for self-assessment of brain performance (brain health) "NouKNOWTM" (pronounced "NOH-NOH", non-medical device).(2) We will provide the customers at Resona with opportunities to build assets and contribute to the local community through investment in Saitama Prefecture bonds, etc., and support them to secure their life by providing an opportunity to regularly check brain performance and maintain brain health by improving lifestyle habits.

Furthermore, Resona and Eisai will collaborate with local governments, companies, universities, public institutions, etc. in Saitama Prefecture through the dementia ecosystem, aiming to co-create value for realizing a sustainable community where citizens of the prefecture can live with peace of mind. For example, to reduce and eliminate anxieties, to enable them to lead a prosperous retirement life, or to enable companies in Saitama Prefecture to engage in efforts for health and productivity management.

(1) This is an investment trust in which Resona makes international diversified investments and ESG investments as a medium- to long-term asset formation support for its customer, as well as investments in Saitama prefectural bonds. Resona provides its customers with the opportunity to participate in the realization of the SDGs and contribute to the local community and society in Saitama Prefecture through their asset management. Resona will meet the needs of its customers who want to contribute to the creation of a society that can withstand the COVID-19 pandemic, by donating a part of the profits of the product to Saitama Prefecture's "COVID-19 Infection Countermeasure Fund" which is the initiative taken by the Saitama Prefecture Office to support the activities of medical professionals and medical institutions.
(2) "NouKNOW" is conducted through a simple card test using a PC or tablet device to quantitatively measure brain performance in four tests evaluating psychomotor function, attention, learning and memory, and working memory. This digital tool allows users to self-assess independently and in a short time frame (approx.15 minutes), enabling regular assessments in instances such as daily life and health checkups. On the results screen, a score (brain performance index (BPI)) - as a measurement of quantified brain performance aspects such as memorization, cognition, and decision - appears along with lifestyle advice for maintaining brain performance.


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 10:33 HKT/SGT
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 17, 2024 19:01 HKT/SGT
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 14:59 HKT/SGT
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: